---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-051430"
form_type: "8-K"
ticker: null
cik: "0001180145"
company_name: "Cardiovascular Systems Inc"
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:21:13.706584+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Abbott completes acquisition of Cardiovascular Systems for $20.00 per share in cash

## Summary
- Each CSI share converted into $20.00 cash; aggregate consideration approx. $850M.
- Stockholders approved merger at special meeting: 34,070,064 for, 123,212 against.
- CSI will be delisted from Nasdaq and deregistered with SEC via Form 25 and Form 15.
- CSI became a wholly-owned subsidiary of Abbott; charter and bylaws amended accordingly.
- Closing occurred April 27, 2023, funded by Abbott's cash on hand.

## SEC filing metadata
- accession: 0001104659-23-051430
- form_type: 8-K
- cik: 0001180145
- company_name: Cardiovascular Systems Inc
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1180145/000110465923051430/0001104659-23-051430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1180145/000110465923051430/tm2313788d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-051430
- JSON: https://secwatch.observer/filing/0001104659-23-051430.json
- Plain text: https://secwatch.observer/filing/0001104659-23-051430.txt

## Key facts
- M&A Transactions
  Cardiovascular Systems Inc completed an acquisition involving Abbott Laboratories for $20.00 per share in cash, approximately $850 million aggregate (closed 2023-04-27).
  - Action: acquisition
  - Counterparty: Abbott Laboratories
  - Consideration: $20.00 per share in cash, approximately $850 million aggregate
  - Closing: 2023-04-27
  source text: as to which appraisal rights were properly exercised (the preceding (a) and (b), collectively, the “ Excluded Shares ”)), was automatically converted into the right to receive $20.00 in cash per Share, without interest (the “ Per Share Merger Consideration ”). Also at the Effective Time, (a) each option to purchase Shares that was outstanding and unexercised
  evidence_url: https://www.sec.gov/Archives/edgar/data/1180145/000110465923051430/0001104659-23-051430-index.htm
- Shareholder Votes
  Cardiovascular Systems Inc shareholders approved Advisory (non-binding) approval of compensation that may be paid or become payable to CSI’s named executive officers that is based on or otherwise relates to the Merger Agreement, the Merger, and the other transactions contemplated by the Merger Agreement at the 2023-04-27 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-04-27
  source text: Proposal 2. The stockholders approved, on an advisory (non-binding) basis, the compensation that may be paid or become payable to CSI’s named executive officers that is based on or otherwise relates to the Merger Agreement, the Merger, and the other transactions contemplated by the Merger Agreement (the “ Compensation Proposal ”). The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows: For Against Abstain Broker Non-Votes 23,646,485 10,319,427 237,884 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1180145/000110465923051430/0001104659-23-051430-index.htm
- Shareholder Votes
  Cardiovascular Systems Inc shareholders approved Approval of the adoption of the Merger Agreement at the 2023-04-27 meeting.
  - Proposal: merger approval
  - Outcome: passed
  - Meeting: 2023-04-27
  source text: Proposal 1. The stockholders approved the adoption of the Merger Agreement. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows: For Against Abstain Broker Non-Votes 34,070,064 123,212 10,520 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1180145/000110465923051430/0001104659-23-051430-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.